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ted to an exhaustive prothrombotic screen
[2]. In all patients, the results of the
screening were negative, thus excluding
the role of prothrombotic alterations in
the development of HIV-associated IPH.
Demonstration of the absence of pro-
thrombotic disorders would further sup-
port the causative role of antiretroviral
treatment (eg, didanosine), as shown by
Kovari et al [1], in the pathogenesis of
HIV-related IPH. In addition, we would
like to point out that there is a high prob-
ability of HIV-infected patients with IPH
developing portal vein thrombosis during
follow-up, and this may further worsen
the existing portal hypertension.
In summary, there are several important
features of HIV-related IPH which may
help the physician differentiate between
cirrhotic portal hypertension and IPH in
an HIV-infected patient who is receiving
highly active antiretroviral therapy. First,
despite clinical evidence of significant por-
tal hypertension, the HVPG in most pa-
tients with HIV-related IPH is normal or
only mildly elevated (!10 mHg). Second,
liver elastography may help to raise the
suspicion of IPH by giving false-negative
results in the assessment of complications
of portal hypertension. Third, these pa-
tients are prone to developing portal vein
thrombosis during follow-up, which calls
for regular screening of portal vein pa-
tency and consideration of anticoagula-
tion. Clinicians should thus be aware of
this emerging phenomenon and institute
the appropriate screening and therapeutic
measures.
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Reply to Chang
and Garcia-Pagan
To the Editor—We thank Chang and
Garcia-Pagan [1] for their interest in our
study [2], and we offer the following reply.
First, in our case-control study of human
immunodeficiency virus (HIV)–infected
patients with noncirrhotic portal hyper-
tension (NCPH), inclusion criteria were
the presence of endoscopically docu-
mented esophageal varices or hepatic ve-
nous pressure gradient (HVPG) 10
mmHg, absence of hepatic cirrhosis on
liver biopsy, and no common cause of liver
disease. All of our case patients had en-
doscopically documented esophageal var-
ices, and no patient was excluded because
of a HVPG !10 mmHg. Eight of 15 case
patients underwent hepatic hemodynamic
evaluation; the median HVPG was 24.5
mmHg (range, 7–54 mmHg). Except in 1
case patient, all HVPG values were 10
mmHg. Second, because most case pa-
tients received a diagnosis of NCPH at a
time before liver elastography was regu-
larly conducted, we did not evaluate liver
stiffness values systematically. Third, we
were not able to search for prothrombot-
ic disorders, because cases were included
retrospectively. However, in contrast to
Chang et al [3], who did not find coag-
ulopathies in their 8 patients, other reports
have noted thrombophilic abnormality in
affected patients [4–6]. This supports a
multifactorial pathogenesis of NCPH in
HIV infection, with antiretroviral therapy
and a prothrombotic state leading to mi-
crothrombosis and vascular obstruction.
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